Vor Biopharma, a pioneer in cancer cell therapy, has recently made headlines as it reestablishes itself after laying off nearly its entire workforce during an operational wind-down last month. The company has emerged under new leadership, with a strategic focus on autoimmune diseases, supported by an impressive $175 million financing package. This renewed direction indicates a significant pivot from its previous endeavors.
The Cambridge, Massachusetts-based Vor Biopharma announced on Wednesday that it has secured exclusive rights to telitacicept, a promising drug candidate that RemeGen has successfully guided through regulatory approvals in China for conditions such as generalized myasthenia gravis (gMG), systemic lupus erythematosus, and rheumatoid arthritis. While RemeGen retains the rights to the drug within China, Vor holds the exclusive rights necessary to develop and commercialize the drug in other territories, which is currently undergoing a global Phase 3 study for gMG that could support an FDA submission.
In cases of gMG, autoantibodies attack critical proteins essential for effective communication between nerves and muscles. This rare disorder manifests as symptoms such as difficulty swallowing and pronounced muscle weakness. The progression of gMG is primarily driven by a type of immune cell known as a B cell. Vor’s innovative drug functions as a fusion protein specifically engineered to selectively inhibit B cell activating factor (BAFF), also referred to as BlyS, and APRIL, both of which are integral to maintaining B cell survival.
While Vor Biopharma is not alone in targeting these pivotal mechanisms, its concentrated approach to gMG could set it apart from competitors in the field. For instance, Novartis has developed zigakibart, a monoclonal antibody that blocks APRIL and is currently in Phase 3 testing for immunoglobulin A nephropathy (IgAN). Similarly, Vera Therapeutics is pursuing BAFF and APRIL inhibition with its fusion protein, atacicept, which recently met its Phase 3 goals in IgAN, with an FDA submission anticipated in the fourth quarter of this year. Additionally, Vertex Pharmaceuticals is advancing its fusion protein, povetacicept, targeting BAFF and APRIL, which was a focal point in its substantial $4.9 billion acquisition of Alpine Immune Sciences.
Recent years have seen the introduction of new therapies for treating gMG, yet none have successfully targeted BAFF and APRIL directly. Available treatments include drugs that inhibit complement proteins associated with gMG, such as AstraZeneca’s Ultomiris and UCB’s Zilbrysq, as well as FcRn inhibitors like Argenx’s Vyvgart and Vyvgart Hytrulo. The latest FcRn inhibitor for gMG, Johnson & Johnson’s Imaavy, received FDA approval in May. Vor has announced that the Phase 3 study for telitacicept is actively enrolling patients across the U.S., Europe, and South America, with preliminary results expected in the first half of 2027.
Vor Biopharma, co-founded by acclaimed oncologist Siddhartha Mukherjee alongside startup incubator PureTech Health, initially focused on developing stem cell-derived therapies for blood cancers, offering alternatives to traditional CART therapies that rely on harvesting and engineering a patient’s own T cells. The company went public in 2021, raising nearly $177 million. However, despite progress in clinical-stage programs, Vor faced financial constraints. In May, the company halted its clinical and manufacturing operations, resulting in the layoff of approximately 95% of its workforce while exploring strategic alternatives for its business model.
Following the recent changes, Vor’s CEO, Robert Ang, resigned on Thursday. The company’s board has appointed Jean-Paul Kress, the former CEO of MorphoSys—which was acquired by Novartis last year—as the new chief executive. Kress also previously led Syntimmune, which was acquired by Alexion Pharmaceuticals, now part of AstraZeneca’s rare diseases subsidiary.
“By targeting BAFF/APRIL signaling with telitacicept, we are making a substantial advancement in treating diseases driven by autoantibodies, distinguishing our therapeutics from other modalities in the market,” Kress stated in a prepared statement. “With this clinically advanced asset, we are uniquely positioned to develop this innovative therapy, with the ambition of making a significant impact for patients battling autoimmune diseases globally.”
In its financial report for the first quarter of 2025, Vor disclosed a cash position of approximately $60 million. Following the telitacicept licensing agreement, the company has bolstered its finances through a $175 million private placement. This financing round includes participation from RA Capital Management, an existing shareholder of Vor, alongside other disclosed investors such as Mingxin Capital, Forbion, Venrock Healthcare Capital Partners, Caligan Partners, and NEXTBio. Vor intends to allocate the proceeds to advance its therapeutic pipeline and for various corporate purposes.
As per Vor’s agreement with RemeGen, Vor is obligated to pay the biotech a total of $125 million, which includes an upfront payment of $45 million along with warrants allowing the purchase of approximately $80 million worth of Vor stock. According to a regulatory filing, RemeGen could earn up to $330 million in regulatory milestone payments and an additional $3.7 billion tied to sales milestones. Moreover, RemeGen will benefit from royalties on sales if the drug successfully reaches the market.
For more insights on the latest trends in litigation, regulation, partnerships, and financial services, consider subscribing to Finance Docket, a collaboration between Breaking Media publications Above the Law and Dealbreaker.
